HOME >> MEDICINE >> NEWS
Mayo Clinic: New recommendations for use of bisphosphonates in treatment of multiple myeloma

ROCHESTER, Minn. -- Mayo Clinic's multiple myeloma (MM) research team has jointly issued a consensus statement regarding the use of bisphosphonates to prevent or treat bone disease in MM. Their recommendations address several controversial issues, including the type of bisphosphonate to be used and the duration of such therapy, and are available in the August issue of Mayo Clinic Proceedings.

"It was imperative that we address the issue that has been under recent intense debate due to patient safety concerns," said Martha Lacy, M.D., Mayo Clinic hematologist and lead author of the statement. "These drugs have far-ranging effects that raised concerns in the medical field, so we brought together the relevant specialists to develop a set of best practice recommendations. We published them in Mayo Clinic Proceedings in order to provide other physicians the benefit of our shared knowledge."

The Mayo Clinic team provided recommendations for the myeloma patients for whom bisphosphonates are indicated. They said pamidronate should be the bisphosphonate of choice for patients who are starting therapy, over the newer, more potent drug zoledronic acid, which is more frequently associated with serious damage to jaw bones. Also in the interest of safety, the team recommended that patients without active disease stop bisphosphonate therapy after two years, and patients with active disease reduce the frequency at which the drugs are given.

MM is a malignant plasma cell disorder that is diagnosed in more than 15,000 people each year in the United States, and which causes more than 11,000 deaths. There are a variety of treatment options for MM, but it remains an incurable disease with current emphasis placed on enhancing quality of life while the cure is sought.

Because bone destruction causes significant problems for MM patients, and painful results include osteoporosis, lytic bone disease and skeletal fractures, clinicians seek t
'"/>


10-Aug-2006


Page: 1 2

Related medicine news :

1. Mayo Clinic: Sinusitis is common yet often overlooked cause of chronic cough
2. Mayo Clinic: Biomarker that may improve quality of life during treatment for colorectal cancer
3. Article outlines current recommendations for treating malaria in the US
4. Drug safety recommendations lack scientific evidence
5. SCAI issues recommendations to prevent kidney damage after imaging procedures
6. New recommendations for the diagnosis of Pulmonary Embolism
7. Latest influenza science and recommendations presented in new release
8. Heart Rhythm Society publishes final recommendations for heart patients
9. UK recommendations on the availability of common painkillers are being contravened
10. NIDA announces recommendations to treat drug abusers, save money and reduce crime
11. Concern over aggressive cholesterol recommendations

Post Your Comments:
(Date:8/1/2014)... 2014 Parker Waichman LLP, a national ... injured by defective medical devices and drugs reports that ... Ethicon surgical power morcellator devices used for the removal ... the spread of cancer associated with power morcellators, according ... 2014. , Johnson & Johnson had previously ceased ...
(Date:8/1/2014)... Aug. 1, 2014 (HealthDay News) -- Almost 140 ... school transportation in the United States. But ... bus-related catastrophes, Dawne Gardner, injury prevention coordinator at ... Center, said in a medical center news release. ... returning to school, it,s important for parents and ...
(Date:8/1/2014)... The evolving healthcare landscape presents ... At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor Pharmacy’s ... resources to enhance patient care and profitability. At ... issues to give independent pharmacists the tools they ... ThoughtSpot show attendance experienced a nearly 70% increase ...
(Date:8/1/2014)... DC (PRWEB) August 01, 2014 ... Thompson (D-CA), Gregg Harper (R-MS), and Peter Welch ... 5380, the Medicare Telehealth Parity Act of 2014, ... fully support this effort to improve healthcare access ... chief executive officer of ATA. "These cost-saving provisions ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 On Monday, ... California NextGen User Symposium in San Francisco, CA. Now ... at the JW Marriott Union Square hotel. , “We ... get up to speed with ACA compliance issues,” Quirk ... month. The symposium provides attendees guidance with NextGen implementation ...
Breaking Medicine News(10 mins):Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2
(Date:8/1/2014)... 1, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Phase 3 study evaluating ISIS-SMN Rx in infants ... cause of infant mortality. Isis plans to dose the ... weeks, at which time Isis will earn an $18 ... The Phase 3 study, ENDEAR, is the first of ...
(Date:8/1/2014)... Pa. , Aug. 1, 2014 Inovio ... will host a conference call to report its second ... at 9:00 AM ET. CEO Dr. J. Joseph ... discuss second quarter earnings, provide a corporate update, and ... will include clinical development plans for VGX-3100, Inovio,s immune ...
(Date:8/1/2014)... Arena Pharmaceuticals, Inc. (NASDAQ: ... reported financial results for the second quarter ended ... continued to see encouraging advancements in the US ... in estimated total prescriptions and estimated total per ... Lief, Arena,s President and Chief Executive Officer. "Other ...
Breaking Medicine Technology:Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 2Inovio Pharmaceuticals to Host Second Quarter 2014 Financial Results Call on August 11, 2014 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
Cached News: